Analysis replicated two-factor structure of the original scale which includes motivation/pleasure and expression deficits. No gender difference was found on the Korean CAINS scores. The Korean CAINS showed adequate convergent validity with the total and subscale scores of the SANS, negative symptoms of BPRS, and self-report measure of behavioral activation. The Korea CAINS also exhibited strong divergent validity as it was minimally related with positive symptoms of the BPRS, depression in the CDSS, and verbal fluency test among neurocognitive tasks. The Korean version of the CAINS demonstrated good reliability and validity and is expected to facilitate studies on the etiology, mechanism, and treatment of negative symptoms in Korean schizophrenia patients. Keywords: CAINS, negative symptoms, schizophrenia, reliability, validity *Corresponding author: Seung-Hwan Lee
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VEGF may have a neuroprotective role in the improvement of schizophrenia or in the treatment effects of antipsychotics The aim of this study was to determine whether or not there was a difference in plasma VEGF levels between patients with schizophrenia and healthy controls. We also explored alterations in plasma VEGF levels in patients with schizophrenia before and after treatment with antipsychotic agents. Method: We examined plasma levels of VEGF in 50 patients with schizophrenia (SPR) and 50 healthy control subjects. We also explored any changes in plasma VEGF levels after 6-week treatment with antipsychotic agents in patients with schizophrenia. All subjects with schizophrenia were either medication-naïve or medication-free for at least 4 weeks before assessment. A trained psychiatrist assessed the psychopathological status of patients using the Positive and Negative Syndrome Scale (PANSS). Results: Plasma VEGF levels in all subjects were significantly correlated with smoking duration, which was considered to be a significant covariate. Pre-treatment plasma VEGF levels in patients with schizophrenia were significantly lower than those in healthy controls. Plasma VEGF levels at baseline were significantly lower in medication-naïve and medication-free patients than in healthy controls (F (2, 97) = 7.779, p = 0.001). After controlling for BMI (p = 0.402) and smoking duration (p = 0.002), VEGF levels in medication-naïve and medicationfree patients were still lower than those in healthy controls (F (2, 95) = 8.181, p = 0.01). Post-treatment VEGF levels were significantly increased in patients with schizophrenia. Plasma VEGF levels in patients with schizophrenia did not exhibit significant correlation with the total or subscale scores of the Positive and Negative Syndrome Scale (PANSS) either at baseline or at the end of the 6-week treatment. Conclusions: Although the mechanism of VEGF in the pathophysiology of schizophrenia has not yet been explained, it may be that VEGF has a neuroprotective role in the improvement of schizophrenia or in the treatment effects of antipsychotics.
